EQUITY RESEARCH MEMO

PrecisionMed

Generated 5/9/2026

Executive Summary

Conviction (model self-assessment)50/100

PrecisionMed is a specialized biospecimen provider and biorepository serving biomedical research, with a focus on neuroscience and oncology. Founded in 1996 and headquartered in San Diego, the company supplies immediately available, well-annotated human biological samples—including cerebral spinal fluid (CSF), serum, plasma, and tissue—paired with detailed clinical data. As a subsidiary of BioIVT, PrecisionMed leverages an extensive network of clinical sites to collect longitudinal samples, supporting translational research and biomarker discovery. The company's long-standing presence and niche focus on high-quality biospecimens make it a reliable partner for academic and pharmaceutical researchers. However, as a private subsidiary, its growth trajectory is closely tied to BioIVT's strategic priorities, and it lacks independent financial disclosures or publicly traded catalysts.

Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)